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Low-Dose of FK 506 and Associated Blood Levels in 
Allotransplantation of Rat Liver, Heart, and Skin 
X. Cai, J. Hamaha, P.N. Rao, J. Flowers, R. Venkataramanan, V. Warty, J.J. Fung, and T.E. Starzl 
THE immunosuppressive properties of FK 506 have been documented in many studies both in vitro and in 
vivo. I Ideal immunosuppression of solid organ transplan-
tation would produce immunologic suppression of the 
allograft recipient without adverse toxic effects. Decreas-
ing the dose of FK 506 to the lowest effective level will 
minimize its side effects. This study attempts to elucidate 
the relationship between low doses of FK 506 and the 
corresponding blood value, and graft survival after treat-
ment cessation in allotransplantation of liver, heart, and 
skin in rat models. 
MATERIALS AND METHODS 
Animals 
Inbred male ACI (Rna) donor and LEW (RTII) recipient (weigh-
ing 250 to 300 g) rats were purchased from Harlan Sprague Dawley 
(Indianapolis. Ind). They were housed in a conventional animal 
facility, and fed commercial rat chow (Wayne Lab Blox F-6, 
Chicago, Ill) and tap water ad libitum. Rats were allowed to 
acclimatize for at least I week before investigation. 
Operative Procedures 
Orthotopic liver transplantation (OL Tx) was performed according 
to the method of Kamada and Calne.2 In brief, the donor liver was 
harvested after the portal vein, infra- and superhepatic venae 
cavae. and bile duct were dissected. Two cuffs were mounted 
onto the portal vein and infrahepatic vena cava. and cannulation 
ofthe bile duct was performed at the same time. The cuffed graft 
was then implanted into an orthotopic position followed by the 
anastomoses of three veins and the bile duct. Rejection was 
determined by recipient jaundice, weight loss, hunched position, 
hard and distended upper abdomen, and eventual death. If rejec-
tion was not confinned by the usual criteria then histopathologic 
examination was used to verify the rejection process. 
Heterotopic heart transplantations (HHTx) were performed by 
the method of Ono and Lindsey.3 Briefty, after harvesting the 
graft, the donor's aorta and pulmonary artery were anastomosed 
to the recipient's abdominal aorta and inferior vena cava in an 
end-to-side fashion with continuous sutures of 10-0 Novatil by 
standard microvascular techniques. Grafted hearts were palpated 
every other day after transplantation and graded as one to four 
plus. Graft rejection was determined by complete cessation of 
heart beat and confinned by gross necropsy. Histopathologic 
examination was carried out only when the gross diagnosis was 
uncertain. 
Full thickness skin transplantation (FTSTx) was performed 
using the method of Barker and Billingham.4 Briefly. a full 
thickness skin graft of2 cm2 was harvested from a donor's tail and 
transplanted onto a muscle-based graft bed of the lateral thoracic 
wall of the recipient. To prevent shearing. a bandage cast was 
applied around the thorax of the recipient. The inspection of grafts 
started on the lOth day postoperatively and was subsequently 
carried out every other day until the graft was rejected. Rejection 
was determined by the absence of residual viable graft. 
Treatment 
FK 506 was supplied by Fujisawa Pharmaceutical Company. 
Osaka. Japan. The FK 506 powder with HCO-6O and o-mannitol. 
was suspended in normal saline. The FK 506 suspension was 
prepared shortly before daily administration. Recipients were 
treated 1M for 14 days after transplantation with FK 506 at doses 
ranging between 0.04 to 1.0 mg!kg. 
Blood Sample Collection 
The first blood sample was collected on day 14 before the last 
treatment. which represented the FK 506 blood value during 
treatment. Three more samples were drawn on days 18,22, and 26 
from three rats in each group. All samples were stored at -80"C 
until measurement. 
FK506 Assay 
The blood level of FK 506 was determined by enzyme-linked 
immunosorbent assay (ELISA) using a mouse monoclonal an-
ti-FK 506 antibody (Fujisawa Pharmaceuticals Co Ltd. Osaka, 
Japan), developed by Tamura et al' and modified by Cadoff et al. 6 
To obtain consistent results. all samples were measured at the 
same time. The lowest detectable limit of FK 506 in rat blood was 
0.8 ng/mL by this assay.7 
Experimental Groups 
Three separate control animal groups (n = 7) were established 
consisting of no immunosuppression. FK 506 (0.04 mg/kg and 0.08 
mg!kg) were given to the OLTx and HHTx recipients for 14 days. 
FK 506 doses varying from 0.16 mg/kg to 1.0 mg/kg were given to 
the FTSTx recipients for the same duration as described above. 
Result Analysis 
Student's I test was used for statistical comparison between 
control and treatment groups. Results are expressed as mean ± 
SO. Statistical significance was defined when P values were 
smallerthan .001. 
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Table 1. Efftcacy of Low-Ooae FK 506 Treatment WHh OLTx, HHTx, and FTSTx 
FKUndeIecIabIe Days Surviving' After 
Transplant FK 506 (mg/kg) Animal No. Survival time (d) MST:t SO (d) TIme (d) FK 506 Undetectable PVaJuet 
Heart Control 7 6.7 x 5 6.86 ± 0.38 
0.04 6 8 x 2.9 x 2. 14. 18 11.0 ± 4.10 N/A .0107 
0.08 6 20.41.61.63.64.65 52.3 ± 18.2 N/A .0001 
Liver Control 8 5.8.9.10.11 x 2. 12. 14 10.0 ± 2.73 
0.04 6 10 x 2. 12.13.16.21 13.7 ± 4.20 NlA .0357 
0.08 6 26.63. >100 x 5 81.5 ± 31.0 N/A .0001 
Skin Control 7 12x2.13x5 12.7 ± 0.49 
0.16 7 12.13 x 2. 15 x 4 14.0 ± 1.29 14 0 .0149 
0.2 7 14 x 4.15.17.21 15.6 ± 2.64 14 1.6 .0077 
0.24 7 14 x 2. 15. 18 x 2. 19.21 17.0 ± 2.71 14 3 .0007 
0.3 7 25 x 7 25.0 ± 0.00 18 7 .0001 
0.6 4 26.32.36.39 33.5 ± 5.57 22 11.5 .0001 
4 29.36.46.46 39.3 ± 8.30 26 13.3 .0001 
Note: FK 506 was given 1M lor 14 days (day 0-13). 
'Days surviving alter FK undetectable - MST - the day at which FK 506 value was not detectable. FK 506 blood valuas were not detectable when the COllcellllldlolle 
were 0.04 to 0.24 rngIkgld. 
tAli P values were determined with Student's t test by comparing treatment group with control group. 
RESULTS 
Liver allografts (n = 8) in the control group were rejected 
around the 10th day (mean survival time [MST] = 10.0 ± 
2.7). When allografted recipients were treated with 0.04 
mg/kg of FK 506 (n = 6), the MST 03.7 ± 4.2 days) was 
almost the same as that in the control group. But, when the 
allografted recipients were treated with 0.08 mglkg of FK 
506 (n = 6), the MST was remarkably increased to 81.5 ± 
31.0 days (P < .0001) (see Table I). The steady-state 
trough FK 506 blood concentrations, however, were too 
low to be detected when the recipients were treated with 
FK 506 doses of either 0.04 mg/kg or 0.08 mg/kg. 
In HHTx, the pattern of graft survival was the same as 
that in OLTx. The heartbeat of grafts stopped on day 6.9 ± 
0.4 in the control group (n = 7). When the recipients 
received 0.04 mg/kg of FK 506 (n = 6), the allografted 
hearts stopped beating on day 11.0 ± 4.1. But, when the 
recipients were treated with 0.08 mglkg of FK 506 (n = 6), 
the heart beating time was significantly prolonged to 52.3 
± 18.2 days (P < .0001) (see Table O. The steady-state FK 
506 levels were below assay detection limits. 
The grafts in FTSTx control group (n = 7) were rejected 
on day 12.7 ± 0.49. After treatment with FK 506 at 0.16, 
0.20, and 0.24 mg/kg (n = 7 in each group), the graft 
survival time was slightly extended to 14.0 ± 1.3, 15.6 ± 
2.6, and 17.0 ± 2.7 days, respectively (P > .0001). How-
ever, when the dose of FK 506 was increased to 0.3, 0.6, 
and 1.0 mg/kg (n = 4 in the last two groups), the MST of 
skin grafts was significantly prolonged to 25.0 ± 0.0, 33.5 
± 5.6, and 39.3 ± 8.3 days, respectively (P < .0001) (see 
Table I). 
FK 506 blood concentration was measurable only when 
the treatment dosage was 0.3 mg/kg or more. Animals 
treated with 0.3 mg/kg of FK 506 exhibited a blood 
concentration of 2.9 ± 0.5 ng/mL during the treatment, 
which was then undetectable on day 18. In the 0.60 mg/kg 
group, FK 506 blood concentration was 6.9 ± 1.5 ng/mL 
during the treatment, 1.8 ± 0.7 ng/mL on day 18, and 
undetectable on day 22. In the 1.0 mg/kg group, it was 7.3 
± 1.2 ng/mL during the treatment. 2.3 ± 1.4 ng/mL on day 
18, 0.8 ng/mL (one sample was 0.8 nglmL, the other two 
were unmeasurable) on day 22, and undetectable on day 26 
(see Fig O. 
The skin allografts were not rejected for a period after 
the FK 506 blood concentration decreased from a detect-
able level to an undetectable one. The graft survival time 
after the levels of FK 506 were no longer detectable (see 
Table 1) was 7 days in the 0.3 mg/kg group, 11.5 days in the 
0.6 mg/kg group, and 13.3 days in the 1.0 mg/kg group. 
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FIg 1. Blood concentration of FK 506 after discontinuation of 
treatment in FTSTx. Full thickness skin transplanted recipients 
EAC~ibtF were treated 1M by FK 506 at the concentrations 
ranging from 0.16 to 1.0 mglkg for 14 days. Blood samples were 
drawn on days 14. 18. 22. and 26. FK 506 blood levels were 
determined by monoclonal antibody-based ELISA. The broken 
lines represented the FK 506 values during treatment. 
LOW-DOSE FK 506 TREATMENT 
DISCUSSION 
Decreasing drug dosage to a lower effective dose is a 
method to limit the side effects of immunosuppression. FK 
506 is a potent immunosuppressive agent, but, unfortu-
nately, it exhibits side effects, such as nephrotoxicity. 8 
Results from this study showed that in the rat OLTx and 
HHTx models, treatment with 0.04 mg/kg of FK 506 did 
not significantly improve the survival time compared with 
that in control group (only 3.7 days in OLTx and 4.1 days 
in HHTx, respectively). But, when the FK 506 dosage was 
increased slightly from 0.04 mglkg to 0.08 mglkg, the mean 
graft survival time was significantly prolonged by 71.5 days 
in OLTx and 45.4 days in HHTx, when compared to the 
control group (P < .0001 for both). These results suggest 
that the effective concentration of FK 506 could be re-
duced to as low as 0.08 mg/kg in liver and heart allotrans-
plantation using the ACI to Lewis strain combination. 
Although the corresponding FK 506 blood level was un-
detectable, the lower dose of FK 506 was still effective in 
prolonging transplant liver and heart survival time in rats. 
This fact indicates a need to develop a more sensitive and 
precise method for measuring the lower effective blood 
concentration of FK 506. Bioassay of FK 506, based on 
the inhibition of an alloreactive T-cell clone proliferation. 
may be a better method, because the assay levels can 
measure lower levels ofFK 506.9 However, this method is 
time consuming and cannot be performed routinely. 
Because the lower effective dose ofFK 506 in OLTx and 
HHTx was too low to be detected, the skin transplant 
model was used to study the relationship between the 
lower dose of FK 506 and its corresponding blood level. 
The results from this experiment showed that 0.3 mglkg of 
FK 506 was the comparatively lower effective dose in 
FTSTx. Meanwhile. this dose of FK 506 demonstrated the 
lowest detectable blood level of FK 506 in rats. When the 
doses of FK 506 were increased from 0.3 to 1.0 mg/kg, the 
blood levels of FK 506 were gradually elevated and the 
graft survival time was significantly prolonged. After ces-
sation of treatment, the higher doses of FK 506 required a 
longer time to reach undetectable levels. 
In addition, these results also showed that the graft 
survival time after the FK 506 blood level became unde-
tectable and the grafts were totally rejected varied accord-
ing to the treatment doses of FK 506. When the doses were 
increased from 0.3,0.6 to 1.0 mg/kg, the graft survival time 
1405 
was prolonged from 7, 11.5 to 13.3 days (see Table I). 
These results suggested that the improved skin graft ac-
ceptance paralleled increased steady state FK 506 concen-
trations, and the graft survival time was dose dependent. 
CONCLUSIONS 
To limit the side effects in FK 506 treatment, the effective 
dose of FK 506 can be reduced to as low as 0.08 mglkg in 
liver and heart allotransplantation in rats when adminis-
tered 1M. It is known that at doses used in this study, FK 
506 is not effective when administered orally. This may be 
related to the differences in the absorbtion of FK 506 from 
the gastrointestinal tract and the 1M site of injection. 
Although improved survival is associated with increasing 
blood FK 506 concentrations, FK 506 is effective even at 
blood steady-state concentrations less than 0.8 nglmL in 
OL Tx and HHTx. Since lower concentrations are effec-
tive, it is necessary to find a more sensitive method for 
measuring the lower effective blood concentration of FK 
506. 
The minimal dose of FK 506 that resulted in detectable 
blood levels was 0.3 mglkg in rats. 
The comparatively lower effective dose of FK 506 in 
preventing skin allograft rejection was 0.3 mglkg. The 
prolonged skin graft survival time was dependent on FK 
506 dosage and its associated blood concentration. 
Although there are no detectable levels of FK 506 in the 
blood after cessation of treatment, there is still a prolon-
gation of graft survival. This effect is augmented with 
increased doses of FK 506. 
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